Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | RGS12 | O14924 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179085 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7544499 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1162502 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17275126 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3468673 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1448490 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3468337 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7352888 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7296911 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7285741 | 0.98 | KDM4E (0.70) | KDM4EALDH1A1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108658792-B | Preparation method of 4-aminobutanol | 河南省化工研究所有限责任公司 | 2021-04-27 | — | — | CN | claimed |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240293391-A1 | ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS | UNIV LEUVEN KATH (BE) | 2024-09-05 | — | — | US | disclosed |
| WO-2024165831-A1 | IMIDAZOLIDONE AND SUCCINIMIDE DERIVATIVES FOR USE AS ALPHA V BETA 3 INTEGRIN INHIBITORS FOR THE TREATMENT OF CANCER | UNIVERSITY OF BRADFORD (GB) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024078581-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND USES THEREOF | APPICINE THERAPEUTICS (HK) LIMITED (CN) | 2024-04-18 | — | — | WO | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-5053548-A | Containing hydroxy substituents; nervous system disorders | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| WO-1991010657-A1 | NEW THIAZOLE DERIVATIVES | CEDONA PHARMACEUTICALS B.V. (NL) | 1991-07-25 | — | — | WO | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| EP-0382213-A2 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-RE32868-E | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
| US-4395417-A | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| US-4211703-A | CHEMICAL INTERMEDIATES FOR CEPHALOSPORINS | SMITHKLINE CORPORATION (US) | 1980-07-08 | — | — | US | disclosed |
| US-4189573-A | CHEMICAL INTERMEDIATES | SMITHKLINE CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
| US-4112086-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885ALDH1A1 2776/4885RAB9A 4270/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885ALDH1A1 2776/4885RAB9A 4270/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885ALDH1A1 2776/4885RAB9A 4270/4885 |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRD3 | KDM4E 553/4885ALDH1A1 2552/4885RAB9A 2738/4885 |
| US-20240293391-A1 | ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS | CXCR4, CCR5, CXCR1 | KDM4E 2358/4885ALDH1A1 1637/4885RAB9A 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.